BioCryst director takes $12.5K retainer in stock

Biocryst director Steven Frank received stock in place of a $12,500 quarterly cash board retainer, increasing his direct holdings to 36,747 shares.

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC (BCRX) reported that director Steven Frank received a grant of 1,288 shares of Common Stock on August 31, 2026 as a grant/award acquisition. The shares were issued at $9.70 per share in lieu of a $12,500 quarterly cash Board Member retainer, bringing his directly held stake to 36,747 shares. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Grant/Award: 1,288 shares

Grant/Award 1 txn

Insider Frank Steven

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	1,288	$9.70	$12K

Holdings After Transaction: Common Stock — 36,747 shares (Direct)

Footnotes (1)

1. F1. Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500.

Key Figures

Shares granted: 1,288 shares Grant price per share: $9.70 per share Quarterly Board Member retainer value: $12,500 +2 more

5 metrics

Shares granted 1,288 shares Common Stock grant/award on August 31, 2026

Grant price per share $9.70 per share Value used for the 1,288-share stock retainer in lieu of cash

Quarterly Board Member retainer value $12,500 Cash retainer fully taken in stock instead of cash

Holdings after transaction 36,747 shares Common Stock directly owned by Steven Frank after the grant

Transaction date August 31, 2026 Date of Common Stock grant/award

Key Terms

in lieu of, quarterly cash Board Member retainer

2 terms

in lieu of financial

"Shares of Common Stock issued to the reporting person in lieu of 100%"

quarterly cash Board Member retainer financial

"100% of the quarterly cash Board Member retainer of $12,500"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BCRX director Steven Frank report?

Steven Frank reported a grant of 1,288 shares of Biocryst Pharmaceuticals Common Stock on August 31, 2026, classified as a grant or award acquisition, increasing his directly held position to 36,747 shares.

At what value was the BCRX stock grant to Steven Frank recorded?

The 1,288 Biocryst Pharmaceuticals shares were issued at $9.70 per share, corresponding to the $12,500 quarterly cash Board Member retainer that was taken in stock instead of cash.

How many BCRX shares does Steven Frank own after this Form 4 transaction?

After the August 31, 2026 grant, Steven Frank directly holds 36,747 shares of Biocryst Pharmaceuticals Common Stock, as reported in the filing.

Was Steven Frank’s BCRX stock grant made under a Rule 10b5-1 trading plan?

No. The filing indicates the Rule 10b5-1 checkbox is not marked, so no Rule 10b5-1 trading plan is reported for this transaction.

What did Steven Frank receive BCRX shares for instead of cash?

He received the 1,288 shares of Biocryst Pharmaceuticals Common Stock in lieu of 100% of a $12,500 quarterly cash Board Member retainer, according to the footnote in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:05 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Frank Steven

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		A		1,288(1)	A	$9.7	36,747	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500.

	/s/ Alane P. Barnes, by power of attorney	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)